Shares In ED Drug Development Company Droop

it would get into the bloodstream extremely quickly

You may have remembered Ukmedix News covering the story of two pharmaceutical companies that had combined to develop a new drug for erectile dysfunction which would work in a completely different way to the other drugs Viagra, Cialis and Levitra. The new drug which is called bremelanotide was particularly exciting because it was to be administered as a nasal inhaler meaning that it would get into the bloodstream extremely quickly and thus produce enhanced sexual function almost immediately.

Well the bad news is that the Food & Drug Administration of America has announced that they have “serious concerns” about the way that the drug has been tested in the clinical trials. The bremelanotide has been extensively tested in phase one and in phase two clinical trials and while the companies King Pharmaceuticals and Palatin Technologies both said that they were happy with the results the Food & Drug Administration felt differently.

The advice from the FDA is that the companies should not bother with phase three testing as there are too many side effects from the bremelanotide drug to make it worthwhile. Among the side effects reported were increases in blood pressure, headaches, nausea and even spontaneous erections that wouldn’t go away.

It appears that there is definitely some form of benefit in using this drug for males who suffer from erectile dysfunction. At the same time the cons seem to outweigh the pros of using this drug as many men report adverse effects when using it. Eventually the companies developing the drug may be forced to announce that there is no commercial potential for it.

This drug was also hyped as a potential drug to cure women who suffer from sexual dysfunction problems and thus the shares of the company were riding extremely high. The fresh news coming from the Food & Drug Administration about the safety concerns have caused the shares to plummet in value.

Ukmedix News will be keeping a watch out for more developments on this erectile dysfunction drug.